The U.S. Food and Drug Administration said it converted its approval of the Alzheimer's drug Leqembi to a traditional approval, allowing the medication to be more widely used.
The FDA added a black-box warning informing patients and health care providers of its safety risks.
Medicare said it would cover a significant portion of the high cost of the drug, a move which is expected to further make it available to more patients.
Teresa Buracchio, an acting director at the FDA said a "confirmatory study verified that it is a safe and effective treatment for patients with Alzheimer's disease."... Read More: WMAR2NEWS